
FDA approves Avacta’s new cancer therapy drug
The US Food and Drug Administration (FDA) has approved Avacta’s Investigational New Drug (IND) application for AVA6000, which will allow the group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States. What is AVA6000? AVA6000 is a novel form of… Read More















